Tan, F.U.Cetinkaya, H.Erden, E.Ulkatan, S.Aydin, N.2020-06-252020-06-252002closedAccess0172-6390https://hdl.handle.net/20.500.12587/2965ULKATAN, SEDAT/0000-0002-9288-7635In patients with hepatitis C virus infection interferon-beta therapy is most effective when administered by the intravenous route. However we would like to present a patient with multiple sclerosis and chronic hepatitis C virus infection who obtained dual benefit from intramuscular interferon-beta therapy. Intramuscular interferon-beta1a (Avonex) 6 million U/week was started for prevention of attacks in a 32-year-old woman with multiple sclerosis. She had acquired hepatitis C virus infection from blood transfusion during a Caesarean section. Although serum transaminases were within normal limits anti-hepatitis C virus test by ELISA and hepatitis C virus RNA by polymerase chain reaction were positive. Liver biopsy revealed chronic persistent hepatitis. Considering the use of interferon-beta1a for multiple sclerosis prophylaxis and the stage of hepatitis the patient was not offered any additional treatment. Repeat liver biopsy performed after one year showed the absence of previous findings. The patient has also cleared the hepatitis-C virus RNA.eninfo:eu-repo/semantics/closedAccesshepatitis Ctreatmentinterferon-betaArticle4948168616872-s2.0-003683991012397766N/AWOS:000178568600057Q3